Navigation Links
Zero-tip

ProductsZero-tip
Company Boston Scientific Corporation
Item Zero-tip
Features 
  • Tipless basket configuration allows close stone proximity for successful retrieval of calyceal calculi.
  • Flat distal surface eliminates tissue-to-tip interface for atraumatic manipulation.
  • Knotted basket tip prevents wire movement for reliable stone capture throughout the urinary tract.
  • Nitinol wire offers a kink-resistant, flexible design for maximum scope deflection.
  • New, low friction sheath design provides smooth scope passage.
  • Multi-layer sheath design allows for thin wall construction, providing uncompromised strength while maintaining flexibility for enhanced scope deflection.
    • Description 
  • Tipless Design
  • ZeroTip basket features a "no tip" design for smooth negotiation and close stone approximation.
  • Flexible Design
  • ZeroTip baskets offers full scope deflection for efficient retrieval of calyceal stones
  • 2.4Fr Diameter Sheath Diameter
  • When passed through a 3.6Fr working channel, a 2.4Fr sheath diameter offers 100% more irrigation capacity than a 3Fr sheath
    • Info Boston Scientific Corporation
    Customer Service: (888) 272-1001
    Web site: http://www.bostonscientific.com

    Related medicine products :

    1. Perc NCircle® Rapid Atraumatic PCNL Stone Extractor
    2. Sentinol™ Self-Expanding Nitinol Biliary Stent System
    3. Strange Cholangiography Set: With N-Circle® Nitinol Tipless Stone Extractor
    4. Common Duct Exploration Set: With N-Circle® Nitinol Tipless Stone Extractor
    5. N-Circle® Nitinol Tipless Stone Extractor
    6. NForce Nitinol Helical Stone Extractors
    7. Ncircle® Nitinol Tipless Stone Extractor with Unidex Handle
    8. Ncircle® Nitinol Tipless Stone Extractor - Helical Basket with Unidex Handle
    9. Ncircle® Nitinol Tipless Stone Extractors - RHR Replacement Stone Extractors
    10. Ncircle® Nitinol Tipless Stone Extractors with Delta Wire®
    11. Escape Nitinol Stone Retrieval Device
    TAG: Zero tip
    Near and far chart set provides letter and number matrix for testing and accommodative vision training. Set includes 1-8 1/2 X 11 chart on white card with black print and 2-3X5 laminated white card w
    Rosenbaum card fits in the pocket (3.5 by 6.5") and shows point, Jaeger and distance equivalents from 20/800 to 20/20. Uses numbers, directional Es and XO patterns. For use at 14" (35 mm). Includes f
    ...ally designed to be a corrected Rosenbaum card. Th...as noted by Horton and Jones in 1997 and others) h... because of the lack of standards associated with ...xaminer can measure a patients single letter near ...
    ...ding card was designed by James Lebensohn, MD and ...uding words, numbers and OX symbols. Optotypes inc... 20/50, 20/40, 20/30, 20/25, and 20/20. Notation e...metric, Jaeger, point size and visual efficiency p...
    Medicine Products:
    (Date:11/21/2008)...fresh from basic training and now serving overseas...fe he saved by donating his rare blood type. , ... Korea (PRWEB) November 21, 2008 -- A local Korean...on saved her life, met for the first time when she...Airman Tamarias Pope, 8th Security Forces Squadron...
    (Date:11/21/2008)...eld on January 8, 2009 , , TORONTO, Nov. 21...Inc. ("MedEmerg") (OTCBB: MDER), one of Canada,s l...ay that it has obtained an interim order from the ...reviously announced plan of arrangement (the "Arra...("AIM") will acquire all of MedEmerg,s outstanding...
    (Date:11/21/2008)...rstCall/ -- Heska Corporation,(Nasdaq: HSKA ) t...iety of,Security Analysts, 12th Annual Biotech an... at 1177 Avenue of the Americas, 2nd Floor in New ...at 9:35 a.m. Eastern Time (7:35 a.m.,Mountain Tim...two weeks,following the presentation through a li...
    (Date:11/21/2008)...gainst Lennox-Gastaut syndrome , , FRIDA...anzel (rufinamide) has been approved as a suppleme...ed Lennox-Gastaut syndrome, the U.S. Food and Drug...l was based on results of a four-month clinical tr...to patients who took a placebo, those who took the...
    Breaking Medicine News(10 mins):Health News:Life-Saving Airman, Leukemia Patient Meet for First Time 2Health News:Life-Saving Airman, Leukemia Patient Meet for First Time 3Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 2Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 3Health News:FDA Approves New Drug for Severe Epilepsy 2
    ...stitute had discovered a new molecular explanation...ed behavior in the disease called porphyria, the d...king George III. The Dana-Farber scientists say i...e August 26 issue of the journal Cell that the nut...
    ...ought of as a as paranormal phenomena, may in fact...ience their own bodies. Despite the high incidence...nown about the phenomenon. Around 10% of the popul...OBE) at some time, typically involving a sensation...
    ...colloborate with Nobex Corporation of United State...cular diseases. The spokesperson of Biocon informe...ollaboration // on Tuesday for development of pept...ar diseases. The Biocon press release said, “The c...
    ... September issue of the Harvard Health Letter, fro... that advocate quick and short working out session...ealth conditions that can lead to diseases. To pre... longer and strenuous workout sessions are require...
    Other Medicine News:Health News:Study Unveils New Insight To The Madness Of King George III 2
    (Date:11/20/2008)...tCall/ -- PAREXEL International Corporation (Nasda...rvices provider, today announced that it has opene...nsulting and clinical research capabilities. With ...ocations throughout five important biopharmaceutic...gentina, Brazil, Chile, and Mexico. This expansion...
    (Date:11/19/2008)...e statistical significance , , ISELIN, N.J....ration (Nasdaq: PARS ) today announced results f...oEmulsion (NE) drug delivery technology formulated... multi-center, randomized, double-blinded, placebo...y of the Company,s 3% Diclofenac Diethanolamine Na...
    (Date:11/19/2008)...m Roche- , , MONTVALE, N.J., Nov. 19 /PRNew...Nasdaq: MEMY ) today announced that it has achie...3487/MEM 3454, its lead alpha-7 nicotinic receptor...schizophrenia (CIAS). The Company has randomized ....0 million payment from its partner Roche. Memory...
    (Date:11/18/2008)...ire-USNewswire/ -- Forty-two leading U. S. scienti...l forum to consider cutting-edge innovations that ...onomy from outbreaks of dangerous zoonotic disease...ng those innovations: , , , , A...at detects highly contagious and dangerous zoonoti...
    Breaking Medicine Technology:PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 342 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Nature study demonstrates that bacterial clotting depends on clustering 5691 1Nature study demonstrates that bacterial clotting depends on clustering 5691 2Excess Weight Seems to Boost Breast Cancer Risk 28489 1Excess Weight Seems to Boost Breast Cancer Risk 28489 2Excess Weight Seems to Boost Breast Cancer Risk 28489 3Mayo Clinics new imaging technology accurately identifies a broad spectrum of liver disease 28487 1Mayo Clinics new imaging technology accurately identifies a broad spectrum of liver disease 28487 2Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 1Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 2Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 3Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 4Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 5Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 6Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 7Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 8Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 9Boceprevir Phase II Study Showed High Rate of Sustained Response With 28 and 48 Week Regimens in Genotype 1 Treatment Naive Hepatitis C Patients 3377 10
    ...h VELCADE, lenalidomide,and dexamethasone , ,KOS, ...um,Pharmaceuticals, Inc. (Nasdaq: MLNM) today repo...ical trials of VELCADE based,therapies that showed... / complete response(1) (CR) rates in newly diagno...e presented at the,prestigious 11th International ...
    ..., 2007 - The drug most,commonly used to arrest pre... another common treatment to cause mild to serious...udy from researchers at,Lucile Packard Children,s ...e. Their findings suggest that, since the effectiv... should consider side,effects more strongly when c...
    Other Medicine Technology:Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 2Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 3Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 4Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 5Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 6Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 7Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 8Common Preterm Labor Drug Has More Side Effects Than Alternative,Finds Study from Packard Children's Hospital and Stanford 2Common Preterm Labor Drug Has More Side Effects Than Alternative,Finds Study from Packard Children's Hospital and Stanford 3Common Preterm Labor Drug Has More Side Effects Than Alternative,Finds Study from Packard Children's Hospital and Stanford 4